150779-71-8
150779-71-8 結(jié)構(gòu)式
基本信息
SDZ 281 977
Benzoic acid, 5-[2-(2,5-dimethoxyphenyl)ethyl]-2-hydroxy-, methyl ester
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-101756 | SDZ281-977 | 150779-71-8 | 1 mg | 1363元 |
| 2026/06/05 | HY-101756 | SDZ281-977 | 150779-71-8 | 5 mg | 3000元 |
| 2026/06/05 | HY-101756 | SDZ281-977 | 150779-71-8 | 10 mg | 4900元 |
常見問題列表
The anticancer profile of SDZ 281-977 is investigated in nude mice bearing the human tumor cell lines A431 (vulvar carcinoma cells), MIA PaCa-2 (pancreatic tumor cells) and MDA-MB-231 (breast carcinoma cells). These cell lines are selected because of their sensitivity for SDZ 281-977. The IC 50 values for inhibition of growth of A431, MIA PaCa-2 and MDA-MB-231 cells are 0.21 μM, 0.29 μM and 0.43 μM, respectively.
Nude mice bearing A431 human vulvar carcinomas receive intravenous injections of SDZ 281-977 (1-10 mg/kg) for 4 weeks. This treatment results in a dose-dependent inhibition of tumor growth. Orally administered SDZ 281-977 (30 mg/kg) induces a 54% inhibition of A431 tumor growth after 3 weeks of treatment. The above regimens are well tolerated. No significant change in body weight occurred during treatment.